Study Description
Survey to be completed independently by HCPs (neurologists treating patients with MS and
MS specialist nurses) and patients/caregivers. The survey- based study is conducting amongst HCPs and patients/caregivers in selected
European countries including Germany, Netherlands, Nordics (Denmark, Sweden), Spain and
Croatia, plus Canada, to evaluate whether HCPs and patients/caregivers receive the
educational materials and to capture their knowledge of specific Mayzent (siponimod)
safety measures.
Eligibility Criteria
Inclusion Criteria:
Physicians will be considered eligible for the survey if they meet the following
screening criteria:
- Care for relapsing MS (RMS) patients
- Personally prescribed disease modifying therapies to MS patients, and;
- Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.
Nurses will be considered eligible for the survey if they:
- Provide supportive care for RMS patients
- Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS
patient.
Patient inclusion criteria include:
- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement
Exclusion Criteria:
-
Study Location
Novartis Investigative Site
Recruiting
Basel,Switzerland
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.